there are always bumps. gordon brown, gillian duffy that sort of thing. there are always problems in elections those leaders have to navigate. you had nick clegg unexpectedly performing well in that tv debate. that is what number ten will hope, that there is a moment i can exploit. will hope, that there is a moment i can exnloit- can exploit. the idea of the liberal democrats can exploit. the idea of the liberal democrats and can exploit. the idea of the liberal democrats and the can exploit. the idea of the liberal democrats and the labour - can exploit. the idea of the liberal democrats and the labour party i can exploit. the idea of the liberall democrats and the labour party are not 100% ruling out any kind of deal coalition. forthe not 100% ruling out any kind of deal coalition. for the liberal democrats at the moment it doesn t make sense for them to say they would enter some kind of deal because realistically there is still time to go and it does look like labou
A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other. The BCG (Bacille Calmette-Guérin) vaccine, created in 1921, remains the sole TB vaccine. While it is 40% to 80% effective in young children, its […] The post The path to a better Tuberculosis vaccine runs through Montana appeared first on Daily Montanan.
Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.
Tina Cascone, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses the impact of the CheckMate 77T study on the treatment approach for non–small cell lung cancer (NSCLC).
The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.